Page 39 - Read Online
P. 39

Okaz et al. Rare Dis Orphan Drugs J. 2025;4:24  https://dx.doi.org/10.20517/rdodj.2025.15  Page 11 of 11

                   depletion. Nat Commun. 2021;12:4358.  DOI  PubMed  PMC
               42.      Osum SH, Oribamise EI, Corbière SMAS, et al. Combining nonsense mutation suppression therapy with nonsense-mediated decay
                   inhibition in neurofibromatosis type 1. Mol Ther Nucleic Acids. 2023;33:227-39.  DOI  PubMed  PMC
               43.      Exploring Nonsense Suppression as a Treatment for NF1. Synapse: syn2164183.  DOI
               44.      Takeda S, Clemens PR, Hoffman EP. Exon-Skipping in Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2021;8:S343-58.  DOI
                   PubMed  PMC
               45.      McCauley ME, Bennett CF. Antisense drugs for rare and ultra-rare genetic neurological diseases. Neuron. 2023;111:2465-8.  DOI
                   PubMed
               46.      Leier A, Moore M, Liu H, et al. Targeted exon skipping of NF1 exon 17 as a therapeutic for neurofibromatosis type I. Mol Ther
                   Nucleic Acids. 2022;28:261-78.  DOI  PubMed  PMC
               47.      Church C. Targeted Exon Skipping of NF1 Exon 52 as a Mutation-Specific Therapeutic for Neurofibromatosis Type 1. 2024 Global
                   NF Conference; 2024 Jun 20-25; Brussels, Belgium. Available from  https://www.ctf.org/wp-content/uploads/2024/06/24_
                   NFConferenceAbstractBook_web.pdf [accessed 26 August 2025].
               48.      Lehtonen A, Howie E, Trump D, Huson SM. Behaviour in children with neurofibromatosis type 1: cognition, executive function,
                   attention, emotion, and social competence. Dev Med Child Neurol. 2013;55:111-25.  DOI  PubMed
               49.      Botero V, Tomchik SM. Unraveling neuronal and metabolic alterations in neurofibromatosis type 1. J Neurodev Disord. 2024;16:49.
                   DOI  PubMed  PMC
               50.      Kim TY, Siesser PF, Rossman KL, et al. Substrate trapping proteomics reveals targets of the βTrCP2/FBXW11 ubiquitin ligase. Mol
                   Cell Biol. 2015;35:167-81.  DOI
               51.      Kohn DB, Chen YY, Spencer MJ. Successes and challenges in clinical gene therapy. Gene Ther. 2023;30:738-46.  DOI  PubMed
                   PMC
               52.      Gao J, Gunasekar S, Xia ZJ, et al. Gene therapy for CNS disorders: modalities, delivery and translational challenges. Nat Rev
                   Neurosci. 2024;25:553-72.  DOI
   34   35   36   37   38   39   40   41   42   43   44